Singapur - anglès - HSA (Health Sciences Authority)

mundipharma pharmaceuticals pte. ltd. - general hospital - betaplast h is a thin and flexible wound dressing made of hydrocolloid. when applied to an exuding wound, the dressing will absorb excess fluid but maintain the wound surface in a moist condition providing a micro-environment that is conductive to healing. it is indicated for pressure ulcers, leg ulcers, diabetic ulcers, traumatic wounds, lacerations, donor and graft sites, burns, post-operative wounds, open surgical wounds, venous stasis ulcers, acute wounds, skin tears, dermatologic disoders and so on.

Singapur - anglès - HSA (Health Sciences Authority)

mundipharma pharmaceuticals pte. ltd. - general hospital - betaplast is a hydrophilic wound dressing made of polyurethane. betaplast is suitable for treatment of medium to heavily exuding wound by selecting its range. betaplast stimulates wound healings and absorbs exudates in wound site while maintaining a moist wound environment compared with a typical dry condition. betaplast provides moderate moisture vapor transmission rate for making skin breath and protecting skin from bacterial invasions and contaminations. it is indicated for pressure ulcers, leg ulcers, diabetic ulcers, traumatic wounds, lacerations, donor and graft sites, burns, post-operative wounds, open surgical wounds, venous stasis ulcers, acute wounds, skin tears, dermatologic disoders and so on.

Singapur - anglès - HSA (Health Sciences Authority)

mundipharma pharmaceuticals pte. ltd. - general hospital - betaplast silver is a hydrophilic wound dressing made of silver impregnated polyurethane. it is used as an aid in creating an anti-microbial environment to prevent infection of a wound site. it is indicated for use over pressure ulcers, leg ulcer, diabetic ulcer, traumatic wounds, lacerations, donor and graft sites, burns, post-operative wound, and venous stasis ulcers.

Singapur - anglès - HSA (Health Sciences Authority)

mundipharma pharmaceuticals pte. ltd. - naloxone 9.00mg eqv naloxone hydrochloride anhydrous; oxycodone 18.00mg eqv oxycodone hydrochloride anhydrous - tablet, film coated, extended release - 10.00 mg/tablet - naloxone 9.00mg eqv naloxone hydrochloride anhydrous 10 mg; oxycodone 18.00mg eqv oxycodone hydrochloride anhydrous 20 mg

Singapur - anglès - HSA (Health Sciences Authority)

mundipharma pharmaceuticals pte. ltd. - naloxone 18.00mg eqv naloxone hydrochloride anhydrous; oxycodone 36.00mg eqv oxycodone hydrochloride anhydrous - tablet, film coated, extended release - 20.00 mg/tablet - naloxone 18.00mg eqv naloxone hydrochloride anhydrous 20 mg; oxycodone 36.00mg eqv oxycodone hydrochloride anhydrous 40 mg

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - oxycodone hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide; citric acid monohydrate; sodium chloride; sodium citrate dihydrate - oxynorm solution for infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - oxycodone hydrochloride, quantity: 50 mg/ml - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; water for injections; sodium hydroxide; sodium chloride; hydrochloric acid - oxynorm solution for infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - oxycodone hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; citric acid monohydrate; hydrochloric acid; sodium chloride; sodium citrate dihydrate; water for injections - oxynorm solution for injection or infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - oxycodone hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium citrate dihydrate; sodium chloride; sodium hydroxide; citric acid monohydrate; water for injections; hydrochloric acid - oxynorm solution for injection or infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

mundipharma pharmaceuticals limited - methoxyflurane - inhalation vapour, liquid - 99.9 %, 3 millilitre(s) - methoxyflurane